RIGHTS ISSUE APRIL-MAY 2019
EVENTS AND PRESENTATIONS
CEO Peter Buhl presents the rights issue at Pressträff Direkt
Pressträff Direkt was recorded on 8 April 2019 in Direkt’s studio in Stockholm, Sweden.
We Work to Cure Cancer
By combining our cutting edge prediction technology with cancer drugs, we offer precision treatment for patients with cancer. Our patients have better chances of living longer and ultimately survive.
TRACK, MATCH & TREAT
Tracking cancers with high precision
It is well known that various cancer types require completely different kinds of treatments. Less known is that each individual patient is unique in terms of which treatment works best. This is partly due to the fact that all humans are unique. An even more important explanation is that on a cellular level, there are several millions of possible causes for tumor development. Oncology Venture tracks the individual cancer to identify its unique characteristics.
Our solid AI technology* in oncology have generated ways to match patients with the relevant treatment.
Matching drugs with patients
As a consequence of the complexity of cancers, it is a significant challenge to match the right treatment to the right patient, both in clinical practice and in drug development. This leads to lower efficacy rates than both patients and doctors could wish for.
Treatments with better efficacy
But cancer is no longer an enigma. And Oncology Venture has the tools to help navigate and make cancer treatment much more precise. Our drug prediction technology improves the efficacy, compared to standard ’one size fits all’ treatments.
ABOUT US
Oncology Venture A/S
By combining our cutting edge prediction technology with cancer drugs, we offer precision treatment for
patients with cancer.
Our patients have better chances of living longer and ultimately survive.
Our results are strong. We have data to prove this. And the prospect is profound.
science
The DRP® Method
By combining cutting-edge science from the fields of genetics and oncology, Oncology Venture is the first to develop a Drug Response Predictor®, which can be combined with ultimately any cancer drug. Using this technology, our offset is treating the particular genetic characteristics of the tumor instead of the type of cancer, which has been the traditional treatment approach. Because cancers are different. Just like people.
Press releases
Oncology Venture A/S stock price (OV.ST)
Oncology Venture A/S is listed on Nasdaq First North in Stockholm with the ticker OV.ST
Oncology Venture has made great strides and our assessment is that via the progress we have made, we are playing in a new league.
Peter Buhl Jensen, CEO
